Exploiting the potential of <i>in situ</i> forming liquid crystals: development and <i>in vitro</i> performance of long-acting depots for peptide drug thymosin alpha 1 subcutaneous administration.

ABSTRACT: The fast-growing filed of long-acting depots for subcutaneous (SC) administration holds significant potential to enhance patient adherence to treatment regimens, particularly in the context of chronic diseases. Among them, injectable in situ forming lyotropic liquid crystals (LCCs) consisting of hexagonal mesophases represent an attractive platform due to their remarkable highly ordered microstructure enabling the sustained drug release. These systems are especially relevant for peptide drugs, as their use is limited by their short plasma half-life and inherent poor stability. In this study, we thus aimed to exploit the potential of a liquid crystalline platform for the sustained release of peptide drug thymosin alpha 1 (Tα1), characterized by a short plasma half-life and with that

SUBMITTER: Vitek M 

PROVIDER: S-EPMC11899226 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature